Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUPNYSE:BHCNASDAQ:CARATSE:TEV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Companies$6.02+9.2%$4.85$3.96▼$9.85$2.23B0.282.61 million shs11.49 million shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4124,800 shs237,144 shsTEVTervitaC$0.00C$1.69▼C$6.46C$672.00MN/A79,738 shs15,893 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Companies0.00%+26.63%+30.19%-15.82%-4.75%CARACara Therapeutics0.00%0.00%0.00%+3.70%-34.76%TEVTervita0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABHCBausch Health Companies3.9726 of 5 stars1.92.00.04.03.13.31.9CARACara Therapeutics0.275 of 5 stars0.00.00.04.20.60.80.0TEVTervitaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ABHCBausch Health Companies 1.86Reduce$7.4223.30% UpsideCARACara Therapeutics 0.00N/AN/AN/ATEVTervita 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TEV, AUP, BHC, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.50(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00BHCBausch Health Companies$9.73B0.23$6.40 per share0.94($0.89) per share-6.76CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00TEVTervitaC$1.36B0.00N/A29.62C$1.58 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Companies-$46M-$0.11N/A1.290.37-0.48%-577.82%5.24%7/30/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ATEVTervitaN/A-C$0.01N/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CompaniesN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ATEVTervitaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02BHCBausch Health CompaniesN/A0.860.62CARACara TherapeuticsN/A4.774.71TEVTervita440.441.000.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Companies78.65%CARACara Therapeutics44.66%TEVTervitaN/AInsider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Companies8.05%CARACara Therapeutics3.10%TEVTervitaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableBHCBausch Health Companies19,900370.08 million338.06 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableTEVTervita36,800115.66 millionN/ANot OptionableTEV, AUP, BHC, and CARA HeadlinesRecent News About These CompaniesTev MonninFebruary 16, 2024 | health.usnews.com'Tu zini, ka tev ir balss'. Dzejniece Inga Gaile par filmu 'Starp revolūcijām'September 2, 2023 | delfi.lv‘Beautiful Mind’ Oscar winner honors his father, Tev Goldsman of Kaua’iAugust 28, 2023 | thegardenisland.comAccelerating Electrons To TeV Levels Using Curved Laser BeamsAugust 7, 2023 | hackaday.comUnderstanding Risk for Venous Thromboembolism (VTE)January 21, 2023 | healthline.comTevva begins mass production of medium-duty electric truckJanuary 13, 2023 | newatlas.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBuy the Dip? 3 Oil Stocks Poised for a Big ComebackBy Chris Markoch | May 22, 2025View Buy the Dip? 3 Oil Stocks Poised for a Big ComebackTEV, AUP, BHC, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Bausch Health Companies NYSE:BHC$6.02 +0.51 (+9.17%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$6.02 +0.01 (+0.17%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Tervita TSE:TEVTervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
